Oxyntomodulin has proven to be very promising with regards to weight loss and improved glucose control, however it has a very short half-life. There is a need of more potent and longer-lived molecules and therefore, we have identified a novel Oxyntomodulin analog known as OXM-001, with a better pharmacological efficacy. In vitro potency of OXM-001 was determined in both GLP-1/Glucagon receptor cell lines using β-Arrestin readout. Zucker Diabetic Sprague Dawley male rats (ZDSD) were treated with vehicle and OXM-001 (100 nmol/kg) every third day (n=6/group). The OXM-001 effects on body weight, food intake, FBG, fasting insulin and HbA1C were examined for three-weeks. HFD female C57BL/6J mice were administrated vehicle, OXM-001 (10 and 30 nmol/kg) and pair-fed to OXM-001 (50 nmol/kg) every third day and MEDI0382 (10 and 30 nmol/kg) everyday (n=8/group). Body weight, food intake and oral glucose tolerance test (OGTT) were assessed during the one-month study. OXM-001 showed to be more potent than stabilized Oxyntomodulin, both over a short 3h stimulation and a long 24h potency test. In ZDSD rats, OXM-001 significantly reduced FBG and HbA1C compared to vehicle group. Furthermore, OXM-001 improved fasting insulin due to the weight loss effect. In C57BL/6J mice, OXM-001 (30 and 50 nmol/kg) significantly reduced weight in a dose-depended manner (12.4% and 23.5% compared to vehicle) and was associated with a decreased energy intake. Both OXM-001 doses showed superiority in weight loss compared to MEDI0382. Interestingly, the pair-fed to OXM-001 lost 16.2 % of its body weight compared to vehicle, showing a superiority of the OXM-001 (50 nmol/kg) to the pair-fed group. Both OXM-001 doses improved glucose control compared to MEDI0382 during the OGTT.

In conclusion, OXM-001 significantly lowered the body weight and improved glucose tolerance in prediabetic rats and fat mice, more potent than MEDI0382, and may therefore represent a possible treatment opportunity for obesity-related co-morbidities.

Disclosure

A. Kayed: None. A. Katri: None. K.V. Andreassen: Employee; Self; Nordic Bioscience. M.A. Karsdal: Stock/Shareholder; Self; Nordic Bioscience. K. Henriksen: Employee; Self; Nordic Bioscience. Employee; Spouse/Partner; Novo Nordisk A/S. Stock/Shareholder; Self; Nordic Bioscience.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.